SNAP-25 (Synaptosomal-Associated Protein 25) is a 206-amino acid peripheral membrane protein that functions as the primary t-SNARE (target SNAP receptor) in the synaptic vesicle fusion machinery. Together with syntaxin-1 and VAMP2, SNAP-25 forms the core SNARE complex that drives Ca²⁺-triggered neurotransmitter release. SNAP-25 is anchored to the presynaptic plasma membrane via palmitoylation of four cysteine residues (Cys 85, 88, 90, 92) and lacks a transmembrane domain, making it unique among SNARE proteins. SNAP-25 dysfunction is implicated in Alzheimer's disease, Parkinson's disease, ALS, and schizophrenia.
| SNAP-25 Protein Overview |
|---|
| Protein Name | Synaptosomal-Associated Protein 25 |
| Gene | [SNAP25](/genes/snap25) |
| UniProt ID | P60880 |
| Chromosomal Location | 20p12.1 |
| PDB Structures | 1KTH, 1X5F, 3IP4 |
| Molecular Weight | ~25.6 kDa |
| Subcellular Localization | Presynaptic plasma membrane (palmitoylated) |
| Protein Family | SNARE family (Q-SNARE, SNAP-25/23/29 subfamily) |
| Tissue Distribution | Brain (hippocampus, cortex, cerebellum), neuroendocrine cells |
SNAP-25 has a distinctive architecture optimized for its role as a membrane-anchored t-SNARE:
- N-terminal region (residues 1-84): Extended coiled-coil forming the first SNARE motif
- Central cysteine-rich domain (residues 85-92): Four palmitoylated cysteines anchoring the protein to membrane
- C-terminal region (residues 93-206): Second SNARE motif forming the coiled-coil bundle
SNAP-25 contributes two α-helical SNARE motifs (SN1 and SN2) to the four-helix SNARE bundle:
| Motif |
Residues |
Role |
| SN1 (N-terminal) |
19-83 |
Forms the first helix of the SNARE bundle; contains the Q-loop |
| SN2 (C-terminal) |
141-202 |
Forms the second helix; completes the t-SNARE core |
This is distinct from VAMP2 (which contributes one helix) and syntaxin-1 (one helix), making SNAP-25 unique as the only SNARE protein contributing two helices.
SNAP-25 is the only SNARE protein without a transmembrane domain:
- Four cysteine residues (Cys 85, 88, 90, 92) are palmitoylated
- Palmitoylation creates a hydrophobic patch that associates with the inner leaflet of the plasma membrane
- The anchoring is reversible — depalmitoylation releases SNAP-25 from the membrane, regulating SNARE complex availability
| Isoform |
Expression |
Distribution |
| SNAP-25a |
Ubiquitous |
Throughout the nervous system |
| SNAP-25b |
Brain-enriched |
Highest in hippocampus and cortex |
- Palmitoylation: Reversible, regulates membrane association and SNARE complex assembly
- Phosphorylation: PKC phosphorylates Ser187, reducing release probability and regulating short-term plasticity
- Oxidation: Reactive oxygen species can modify cysteine residues, disrupting palmitoylation and membrane association
SNAP-25 is essential for Ca²⁺-triggered neurotransmitter release:
Vesicle Priming
- SNAP-25 recruits synaptic vesicles to release sites at the active zone
- It interacts with Munc18 and Munc13 to form the primed SNARE complex
- Primed vesicles are held in a fusion-ready state by the partial SNARE complex
SNARE Complex Assembly
- SNAP-25 and syntaxin-1 form the t-SNARE complex (heterodimer) at the plasma membrane
- VAMP2 on the synaptic vesicle engages with the t-SNARE complex
- The ternary SNARE complex (SNAP-25 + syntaxin-1 + VAMP2) zippers from N- to C-terminus
- This mechanical force drives fusion pore opening
- NSF and α-SNAP disassemble the post-fusion complex for recycling
Neurotransmitter Release
- SNAP-25 is required for quantal content release
- Loss of SNAP-25 severely impairs synchronous release
- Asynchronous release is partially preserved
SNAP-25 is a hub for synaptic plasticity modulation:
- PKC Phosphorylation: Ser187 phosphorylation by PKC reduces SNARE complex stability
- Short-Term Plasticity: PKC-dependent SNAP-25 modulation affects paired-pulse ratio
- Long-Term Potentiation: Activity-dependent SNAP-25 phosphorylation contributes to LTP
- Homeostatic Scaling: Chronic activity changes alter SNAP-25 expression and palmitoylation
¶ Regional and Cellular Distribution
- Brain Regions: Highest expression in hippocampus, cerebral cortex, cerebellar cortex
- Cell Types: Excitatory glutamatergic and inhibitory GABAergic neurons
- Subcellular: Concentrated at the presynaptic active zone and synaptic vesicle membranes
SNAP-25 dysfunction contributes to synaptic failure in AD:
Synaptic Loss
- Post-mortem AD brains show reduced SNAP-25 protein levels in the hippocampus and cortex
- SNAP-25 loss correlates with cognitive decline (MMSE scores) and Braak staging
- CSF SNAP-25 fragments serve as a biomarker of synaptic degeneration
Aβ Oligomer Effects
- Aβ oligomers impair SNAP-25/syntaxin-1/VAMP2 interactions in lipid mixing assays
- Aβ disrupts SNAP-25 palmitoylation and membrane association
- This reduces the pool of fusion-competent t-SNARE complexes
SNARE Complex Disruption
- Aβ treatment reduces the stability of the ternary SNARE complex
- Impaired SNARE assembly reduces release probability
- Synaptic vesicles fail to fuse efficiently, reducing neurotransmitter release
CSF Biomarker Applications
- SNAP-25 cleavage fragments in CSF indicate synaptic degeneration
- CSF SNAP-25 complements Aβ42 and tau biomarkers for AD diagnosis
- Longitudinal SNAP-25 changes track cognitive decline progression
SNAP-25 dysfunction contributes to dopaminergic terminal vulnerability in PD:
Striatal Terminal Deficits
- Reduced SNAP-25 protein in striatal terminals of PD models
- Loss of dopaminergic terminals reduces vesicular dopamine content
- Impaired SNAP-25 function reduces the efficiency of dopamine release
Alpha-Synuclein Interaction
- α-Synuclein may interfere with SNAP-25 SNARE complex assembly
- α-Syn overexpression reduces SNAP-25 mobility at the active zone
- This contributes to the dopamine release deficit in PD
Therapeutic Potential
- Enhancing SNAP-25 function could improve synaptic transmission in early PD
- Stabilizing the SNAP-25/SNARE complex is a therapeutic strategy
Motor Nerve Terminals
- Impaired SNAP-25-dependent exocytosis at motor nerve terminals
- Defects in presynaptic function at the neuromuscular junction (NMJ)
- Altered SNAP-25 expression in ALS spinal cord motor neurons
Neurodegeneration Links
- TDP-43 pathology affects SNAP-25 expression in motor neurons
- Synaptic dysfunction may be an early event in ALS progression
- SNAP-25 as a potential biomarker for motor neuron disease
SNAP25 gene polymorphisms are linked to schizophrenia risk:
- Specific SNAP25 haplotypes increase susceptibility
- SNAP25 variants affect working memory and cognitive function
- Altered SNAP-25 in prefrontal cortex may contribute to psychotic symptoms
¶ Diagnostic and Biomarker Applications
SNAP-25 fragments in CSF indicate synaptic degeneration:
- AD Diagnosis: CSF SNAP-25 complements Aβ42 and tau biomarkers
- Disease Progression: Longitudinal changes track cognitive decline
- Sensitivity: SNAP-25 changes appear early in disease course
- PET Tracers: SNAP-25-targeted PET agents are under development
- Synaptic Density: SNAP-25 expression correlates with synaptic density measures
- SNAP-25 levels may serve as a pharmacodynamic marker for drugs targeting synaptic function
- Changes in CSF SNAP-25 reflect treatment effects on synaptic integrity
| Approach |
Mechanism |
Status |
Indication |
| Botulinum Toxin A |
Cleaves SNAP-25 |
FDA-approved |
Dystonia, spasticity, migraines |
| Botulinum Toxin C |
Cleaves SNAP-25 |
Research |
Experimental therapeutic |
| SNAP-25 Enhancers |
Increase expression and function |
Preclinical |
AD, PD |
| PKC Modulators |
Regulate Ser187 phosphorylation |
Preclinical |
Modulate release probability |
| SNARE Complex Stabilizers |
Enhance SNAP-25-Syntaxin-1-VAMP2 interaction |
Research |
Neuroprotection |
- AAV-SNAP25: Enhancing SNAP-25 expression to restore synaptic function in neurodegeneration
- Palmitoylation Modulators: Enhancing SNAP-25 membrane association
- Splice-Modulating: Targeting disease-specific SNAP25 splice variants
Botulinum neurotoxins (BoNT/A, BoNT/C) cleave SNAP-25 at distinct sites:
- BoNT/A cleaves SNAP-25 at the C-terminal region (residue 197)
- BoNT/C cleaves at the N-terminal region (residue 253 in the longer isoform)
- Cleavage prevents SNAP-25 from forming the SNARE complex
- This blocks acetylcholine release, producing muscle paralysis
- Therapeutic use: Dystonia, spasticity, chronic pain, chronic migraine